Clinical Trial Update: A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. [Phase 2]

View source ↗

Summary

A 4-year extension study of deferasirox for iron chelation in pediatric β-thalassemia major patients with transfusional iron overload completed, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia Major
• Transfusional Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Iron Overload, β-thalassemia Major | Phase 2 | Status: COMPLETED | Results posted: 2011-08-15